Researchers uncover early adherence step in intestinal transit of Shigella
(Massachusetts General Hospital) The recent discovery of an early adherence step in the infection cycle could provide a new therapeutic target or even a new method for vaccine development.
The Journal of Physical Chemistry BDOI: 10.1021/acs.jpcb.0c01595
This study contributes to a better understanding of growth, survival, and disease mechanism at molecular level and provides potential new targets for designing drugs against Shigella infection.
Conditions: Diarrhea; Diarrhea Infectious Intervention: Other: no intervention Sponsors: Centre for Infectious Disease Research in Zambia; European Vaccine Initiative; Groupe de Recherche Action en Sante Not yet recruiting
Publication date: May 2020Source: Molecular Immunology, Volume 121Author(s): Yrvin León, Lionel Zapata, Alexis Salas-Burgos, Angel Oñate
Publication date: Available online 17 February 2020Source: International Journal of PharmaceuticsAuthor(s): Yadira Pastor, Isaiah Ting, Ana Luisa Martínez, Juan Manuel Irache, Carlos GamazoAbstractThermosensitive hydrogels have been studied as feasible needle-avoidance alternative to vaccine delivery. In this work, we report the development of a new thermal-sensitive hydrogel for intranasal vaccine delivery. This delivery system was formulated with a combination of the polymer Gantrez® AN119 and the surfactant Pluronic® F127 (PF127), with a high biocompatibility, biodegradability and immunoadjuvant propertie...
Abstract Vaccine implementation planning in low- and middle-income countries (LMIC) often focuses on children without considering special adult populations. We adapted an economic model developed by the United States Department of Defense (DoD) to evaluate the cost-effectiveness of vaccine acquisition strategies for Campylobacter-, ETEC-, Shigella-, and norovirus-associated gastroenteritis. We compared implementation costs with current medical management in the Peruvian armed forces, a special population of low- and middle-income (LMIC) adults with a high incidence of infectious gastroenteritis. Pathogen-specific ...
Conditions: Immunisation; Shigella Infection Interventions: Other: Placebo; Biological: Shigella sonnei strain 53G; Biological: WRSs2 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting